CR9577A - Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil) - Google Patents

Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)

Info

Publication number
CR9577A
CR9577A CR9577A CR9577A CR9577A CR 9577 A CR9577 A CR 9577A CR 9577 A CR9577 A CR 9577A CR 9577 A CR9577 A CR 9577A CR 9577 A CR9577 A CR 9577A
Authority
CR
Costa Rica
Prior art keywords
chlorophenyl
immediate release
pharmaceutical formulations
load
high drug
Prior art date
Application number
CR9577A
Other languages
English (en)
Inventor
Thomas Backensfeld
Torsten Wagner
Kai Juergens
Adrian Funke
Kai Thode
Heiko Kranz
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR9577A publication Critical patent/CR9577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Formulaciones farmaceuticas solidas de liberacion inmediata y con una carga de droga elevada que comprenden (4-clorofenil)[4-(piridilmetil)-ftalazin-1-ilo] micronizado, asi como sus sales aceptables para uso farmaceutico.
CR9577A 2005-06-07 2007-12-07 Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil) CR9577A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05090167A EP1731154A1 (en) 2005-06-07 2005-06-07 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)|4-(4-pyridylmethyl)pht halazin-1-yl| and salts thereof

Publications (1)

Publication Number Publication Date
CR9577A true CR9577A (es) 2008-03-06

Family

ID=34938468

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9577A CR9577A (es) 2005-06-07 2007-12-07 Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)

Country Status (22)

Country Link
EP (2) EP1731154A1 (es)
JP (1) JP2008542421A (es)
KR (1) KR20080017443A (es)
CN (1) CN101242841A (es)
AR (1) AR054377A1 (es)
AU (1) AU2006256853A1 (es)
BR (1) BRPI0611818A2 (es)
CA (1) CA2610977A1 (es)
CR (1) CR9577A (es)
CU (1) CU20070272A7 (es)
DO (1) DOP2006000128A (es)
EC (1) ECSP078037A (es)
GT (1) GT200600243A (es)
IL (1) IL187906A0 (es)
MX (1) MX2007015495A (es)
NO (1) NO20080066L (es)
PE (1) PE20070012A1 (es)
RU (1) RU2007147953A (es)
TW (1) TW200716114A (es)
UY (1) UY29585A1 (es)
WO (1) WO2006131394A1 (es)
ZA (1) ZA200800113B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958615A1 (en) * 2007-02-13 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Solid pharmaceutical formulations of a homogeneous dispersion of active principles having pH-dependent solubility
EP1958616A1 (en) * 2007-02-13 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical formulations of 1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine or salts thereof
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
AU3980499A (en) 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases

Also Published As

Publication number Publication date
CN101242841A (zh) 2008-08-13
GT200600243A (es) 2007-07-16
UY29585A1 (es) 2007-01-31
RU2007147953A (ru) 2009-07-20
IL187906A0 (en) 2008-03-20
WO2006131394A1 (en) 2006-12-14
CA2610977A1 (en) 2006-12-14
MX2007015495A (es) 2008-02-22
AU2006256853A1 (en) 2006-12-14
ZA200800113B (en) 2009-07-29
KR20080017443A (ko) 2008-02-26
JP2008542421A (ja) 2008-11-27
EP1888073A1 (en) 2008-02-20
CU20070272A7 (es) 2010-09-30
AR054377A1 (es) 2007-06-20
ECSP078037A (es) 2008-01-23
DOP2006000128A (es) 2006-12-15
BRPI0611818A2 (pt) 2010-09-28
PE20070012A1 (es) 2007-02-07
EP1731154A1 (en) 2006-12-13
NO20080066L (no) 2008-03-06
TW200716114A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
CR10160A (es) Arildihidroisoquinolinas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
CL2008002051A1 (es) Compuestos derivados de isoxazol-4-metoxi, triazol-4-metoxi o pirazol-4-metoxi, con actividad agonista del receptor x de farnesoide (fxr); composicion farmaceutica que los contiene; y el uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento de dislipidemia y enfermedades relacionadas.
UY30163A1 (es) Nuevas ariltienopirimidinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos
MX2009010289A (es) Composiciones para administracion nasal.
CR10573A (es) Derivados del pirazol como inhibidores del citocromo p450
ECSP077243A (es) Formulación de pelet de liberación extendida que contiene pramipexol o una de sus sales farmacéuticamente aceptable, un método para su fabricación y su uso
UY32203A (es) Amino pirimidinas y su uso en terapia
ECSP088296A (es) Compuestos terapéuticos
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
PT2043600T (pt) Formulações farmacêuticas para a libertação prolongada de princípio(s) ativo(s), assim como suas aplicações, nomeadamente terapêuticas
FR2949062B1 (fr) Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
UY30165A1 (es) Nuevas arildihidroisoquinolinonas sustituidas con aminolcoholes, procedimiento para su preparación y su uso como medicamentos
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
SV2009003366A (es) Estabilizacion de vitamina b12
AR082493A1 (es) Formulaciones a base de nalbufina, y sus utilizaciones
NI201000189A (es) Formulación de medicamento sólido con liberación retardadas.
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY31839A (es) Compuestos
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
ECSP13012832A (es) Compuestos de pirazol como antagonistas de crth2
CR9577A (es) Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
AR058047A1 (es) Administracion de inhibidores de dipeptidil peptidasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)